Honestly, I believe AMRN will become cash flow positive at some point.
Of course, a BP BO is the only way to optimize the uptake of Vascepa,
and that is not very likely until Denner finds a way to entice BP into paying
a reasonable price for the company. If BP acquired AMRN I still believe it
could eventually bring in $2 billion in revenues annually. China is a wild card,
but there too I think the right BP owning AMRN could do a great deal to help
Eddingpharm turn Vascepa into a winner there as well. Denner has a very
strong science background so he certainly understands what the potential
is. He does not need to get there with a GIA strategy (which is suicide.)
Denner simply needs to get AMRN to the point where BP sees that they
could make Vascepa (or its "new formulation") into a blockbuster product...
Be that in Europe, China, or the US.
Market Data 
Markets 
AI
